In a press release issued earlier this afternoon, the time zone of the FPWR Research Symposium presentation was labeled as Central Time. The correct time zone is Mountain Time.
The corrected press release is posted below.
REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced an oral presentation at the Foundation for Prader-Willi Research (FPWR) 2023 Research Symposium, being held October 5-6, 2023, in Denver, Colorado. The presentation features results from the recently completed randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS).
Presentation details can be found below:
FPWR 2023 Research Symposium
Title: | Rationale for and Results from a Randomized Withdrawal Period Following Long-Term Administration of Diazoxide Choline Extended-Release Tablets to People with Prader-Willi Syndrome |
Presenter: | Jennifer L. Miller, M.D. (University of Florida) |
Format: | Oral Presentation |
Date/Time: | Thursday, October 5, 2023 at 2:00 – 2:20 PM MDT |
Location: | Westin, Downtown Denver |
Livestream: | Click Here |
About PWS
The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, food pre-occupation, extreme drive to food seek ...